Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 45, 2008, Pages 17481-17486

  Kruschinski, Anna ^a   Moosmann, Andreas ^b   Poschke, Isabel ^c   Norell, Håkan ^c,d   Chmielewski, Markus ^e   Seliger, Barbara ^f   Kiessling, Rolf ^c   Blankenstein, Thomas ^a,g   Abken, Hinrich ^e   Charo, Jehad ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF COLOGNE   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Immunotherapy; In vivo imaging; Retroviral transduction; Tolerance; Tumor biology

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RAG2 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CARCINOMA; CELL ACTIVATION; CHIMERA; CONTROLLED STUDY; CYTOKINE RELEASE; DEGRANULATION; EX VIVO STUDY; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC ENGINEERING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

ANIMALS; CARCINOMA; DNA-BINDING PROTEINS; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LUCIFERASES; MICE; MICE, KNOCKOUT; RECEPTOR, ERBB-2;

MUS;

EID: 56249128626     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804788105     Document Type: Article

References (44)

1. Charo J, et al. (2005) Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res 65:2001-2008.
2. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299-308.
3. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immun 3:999-1005.
4. Restifo NP, et al. (1996) Loss of functional β 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100-108.
5. Gladow M, Uckert W, Blankenstein T (2004) Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors. Eur J Immunol 34:1882-1891.
6. Trinchieri G (1989) Biology of natural killer cells. Adv Immunol 47:187-376.
7. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225-274.
8. Yokoyama WM, Kim S (2006) Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 214:143-154.
9. Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675-678.
10. Moretta A, Moretta L (1997) HLA class I specific inhibitory receptors. Curr Opin Immunol 9:694-701.
11. Wilson JL, et al. (1999) NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol 163:4207-4212.
12. Lanier LL (2006) Natural killer cells: Roundup. Immunol Rev 214:5-8.
13. Menard S, Pupa SM, Campiglio M, Tagliabue E (2003) Biologic and therapeutic role of HER2 in cancer. Oncogene 22:6570-6578.
14. Meric-Bernstam F, Hung MC (2006) Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 12:6326-6330.
15. Slamon DJ, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
16. Finn RS, Slamon DJ (2003) Monoclonal antibody therapy for breast cancer: Herceptin. Cancer Chemother Biol Response Modif 21:223-233.
17. Slamon DJ, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
18. Perussia B, et al. (1987) Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul 6:171-188.
19. Porgador A, Mandelboim O, Restifo NP, Strominger JL (1997) Natural killer cell lines kill autologous β2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy. Proc Natl Acad Sci USA 94:13140-13145.
20. Raulet DH (2006) Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol 18:145-150.
21. Parham P (2006) Taking license with natural killer cell maturation and repertoire development. Immunol Rev 214:155-160.
22. Johansson MH, Hoglund P (2006) The dynamics of natural killer cell tolerance. Semin Cancer Biol 16:393-403.
23. Ruggeri L, Aversa F, Martelli MF, Velardi A (2006) Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev 214:202-218.
24. Koh CY, et al. (2001) Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97:3132-3137.
25. Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98:11521-11526.
26. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-171.
27. Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B (2002) Tuning tumor-specific T-cell activation: A matter of costimulation? Trends Immunol 23:240-245.
28. Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214:73-91.
29. Vales-Gomez M, Reyburn H, Strominger J (2000) Molecular analyses of the interactions between human NK receptors and their HLA ligands. Hum Immunol 61:28-38.
30. Robert N, et al. (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786-2792.
31. Choudhury A, et al. (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108:71-77.
32. Neve RM, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527.
33. Stein MN, Shin J, Gudzowaty O, Bernstein AM, Liu JM (2006) Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. Anticancer Res 26:1759-1763.
34. Yamaguchi Y, et al. (2005) HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab. Anticancer Res 25:827-832.
35. Carson WE, et al. (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31:3016-3025.
36. Imai C, Iwamoto S, Campana D (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106:376-383.
37. Suck G (2006) Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 16:412-418.
38. Uherek C, et al. (2002) Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100:1265-1273.
39. Miller JS, et al. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051-3057.
40. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H (2004) T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 173:7647-7653.
41. Hombach A, Heuser C, Abken H (2003) Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy. Methods Mol Biol 207:365-381.
42. Van Parijs L, Refaeli Y, Abbas AK, Baltimore D (1999) Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes. Immunity 11:763-770.
43. Morgan RA, et al. (2003) High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171:3287-3295.
44. Charo J, et al. (1999) A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene. J Immunol 163:5913-5919.